Washington D.C, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative™ (QLHC), a non-profit organization and sponsor of the I-SPY 2.2 TRIAL™, presented an overview of the remarkable ...
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback